

Special Issue

Novel Therapies for the Treatment of Inflammatory Bowel Disease

Message from the Guest Editors

It is well known that inflammatory bowel disease can be a heterogeneous condition with great diversity in presentation, disease course, and response to treatment. For patients that have a poor treatment response or experience adverse events relating to certain drug regimens, novel efficacious therapies may be utilised to provide symptom relief and reduce disease activity. Novel therapies include emerging treatments that are still in the experimental stage, newly approved therapies, treatments that have been effective in other inflammatory conditions and have a role in IBD, and isolated therapies that have been successfully implemented for certain individuals. We invite papers that report quantified outcomes on the implementation of novel therapies and welcome original studies, systematic reviews and meta-analyses, case-reports, and scoping reviews.

Guest Editors

Dr. Angharad Vernon-Roberts

Department of Paediatrics, University of Otago Christchurch, Christchurch, New Zealand

Prof. Dr. Andrew Day

Department of Paediatrics, Christchurch Hospital, University of Otago, Christchurch 4710, New Zealand

Deadline for manuscript submissions

25 December 2025



Gastrointestinal Disorders

an Open Access Journal
by MDPI

Impact Factor 0.8
CiteScore 1.2



mdpi.com/si/240079

Gastrointestinal Disorders
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
gastrointestdisord@mdpi.com

[mdpi.com/journal/
gastrointestdisord](https://mdpi.com/journal/gastrointestdisord)





Gastrointestinal Disorders

an Open Access Journal
by MDPI

Impact Factor 0.8
CiteScore 1.2



[mdpi.com/journal/
gastrointestdisord](https://mdpi.com/journal/gastrointestdisord)



About the Journal

Message from the Editor-in-Chief

Editor-in-Chief

Prof. Dr. Richard W. McCallum

1. Department of Medicine, Texas Tech University Health Sciences Center, El Paso, TX 79905, USA
 2. Department of Internal Medicine, Texas Tech University Medical Center, Paul L. Foster School of Medicine, El Paso, TX 79905, USA
 3. School of Medicine, University of Queensland, Brisbane, Australia
-

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions; authors retain copyright.

High Visibility:

indexed within Scopus, ESCI (Web of Science), FSTA, and other databases.

Journal Rank:

CiteScore - Q2 (Immunology and Microbiology
(miscellaneous))